查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576770

融合蛋白市場，按產品類型、應用、最終用戶、治療領域 - 全球預測 2025-2030

Fusion Proteins Market by Product Type (Chemically Synthesized Fusion Proteins, Recombinant Fusion Proteins), Application (Diagnostic Applications, Research Applications, Therapeutic Applications), End User, Therapeutic Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

按產品類型、應用、最終用戶和治療領域分類，2023 年融合蛋白市場價值為 270.2 億美元，預計到 2024 年將達到 295.8 億美元，複合年成長率為 10.49%，預計將達到 2024 年。為543.4億。

從產品類型、應用、最終用戶和治療領域來看，融合蛋白是生物技術的革命性進步，是由兩種不同的蛋白質序列基因融合形成的人工蛋白質，具有多方面的生物學功能，從而形成單一的多肽鏈。該技術增強了標靶遞送和治療功效，使其在腫瘤學、自體免疫疾病和酵素替代療法等領域至關重要。其應用範圍廣泛，可用於藥物開發、藥物傳輸系統、診斷，甚至農業。最終用戶主要是製藥公司、生技公司、研究機構和醫療機構。由於對新型生技藥品的需求不斷增加、基因工程的進步以及生物技術領域投資的增加，按產品類型、應用、最終用戶和治療領域分類的融合蛋白市場預計將顯著成長。主要成長動力包括慢性病的流行、對具有成本效益的生物製藥的需求以及蛋白質工程的技術進步。在免疫療法和個人化醫療的發展中，由於對標靶治療的需求，商機正在迅速增加。然而，仍存在阻礙市場成長的挑戰，例如高昂的研發成本、嚴格的監管條件和複雜的製造流程。道德問題和專利問題也是限制因素。為了取得成功，公司應該專注於 CRISPR、人工智慧主導的蛋白質設計等創新技術，以及提高融合蛋白的特異性和穩定性的先進分子技術。與學術和研究機構的聯盟與合作也可以促進新發現和產品開發。市場是動態的，其特點是快速的技術進步和競爭力量，這要求企業保持靈活性和適應能力。合成生物學領域的創新和開拓新的治療領域來解決未滿足的需求可以提供利潤豐厚的成長途徑。有抱負的公司應該採取利用這些創新的策略，並簡化生產和監管流程，以實現最佳的市場滲透。

主要市場統計
基準年[2023] 270.2億美元
預測年份 [2024] 295.8億美元
預測年份 [2030] 543.4億美元
複合年成長率（%） 10.49%

市場動態：快速發展的融合蛋白市場，按產品類型、應用、最終用戶和治療領域揭示關鍵市場洞察

按產品類型、應用、最終用戶和治療領域分類，融合蛋白市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 在按產品類型、應用、最終用戶和治療領域使用融合蛋白的新型治療方法擴大採用，用於慢性疾病的標靶治療
    • 癌症和自體免疫疾病盛行率上升推動了對先進融合蛋白療法的需求
    • 支持擴大藥品製造能力和融合蛋白生產的創新技術
  • 市場限制因素
    • 按產品類型、應用、最終用戶和治療領域分類的融合蛋白開發和生產成本較高
  • 市場機會
    • 按產品類型、應用、最終用戶和治療領域擴展生物製藥研究，並專注於多功能融合蛋白
    • 增加生技研發投資，依產品類型、應用、最終用戶和治療領域開發下一代融合蛋白
  • 市場挑戰
    • 按產品類型、應用、最終用戶和治療領域對融合蛋白的生產和商業化提出嚴格的監管要求

波特五力：依產品類型、應用、最終用戶和治療領域開拓融合蛋白市場的策略工具

波特的五力框架是了解融合蛋白市場、按產品類型、應用、最終用戶和治療領域分類的競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更具彈性的市場地位。

PESTLE分析：了解融合蛋白市場、產品類型、應用、最終用戶和治療領域的外部影響

外部宏觀環境因素在塑造融合蛋白市場、產品類型、應用、最終用戶和治療領域的性能動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解融合蛋白市場、產品類型、應用、最終用戶和治療領域的競爭格局

按融合蛋白市場、產品類型、應用、最終用戶和治療領域進行詳細的市場佔有率分析，可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質融合蛋白市場，按產品類型、應用、最終用戶和治療領域分類的供應商績效評估

FPNV 定位矩陣是根據融合蛋白市場、產品類型、應用、最終用戶和治療領域評估供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，按產品類型、應用、最終用戶和治療領域繪製融合蛋白市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，按產品類型、應用、最終用戶和治療領域對融合蛋白市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 按產品類型、應用、最終用戶和治療領域更多地採用利用融合蛋白的新治療方法，用於慢性疾病的標靶治療
      • 癌症和自體免疫疾病發生率的上升推動了對先進融合蛋白療法的需求
      • 支持擴大藥品製造能力和融合蛋白生產的創新技術
    • 抑制因素
      • 按產品類型、應用、最終用戶和治療領域分類的融合蛋白開發和生產成本較高
    • 機會
      • 擴大生物製藥研究，重點關注融合蛋白產品類型、應用、最終用戶和治療領域的多功能性
      • 增加生技研發投資，依產品類型、應用、最終用戶和治療領域開發下一代融合蛋白
    • 任務
      • 按產品類型、應用、最終用戶和治療領域對融合蛋白的生產和商業化提出嚴格的監管要求
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章融合蛋白市場：依產品類型

  • 化學合成的融合蛋白
  • 重組融合蛋白

第7章融合蛋白市場：依應用

  • 診斷用途
    • 疾病診斷
  • 研究用途
    • 藥物開發
    • 蛋白質體學研究
  • 治療應用
    • 自體免疫疾病
    • 腫瘤學
      • 癌症免疫治療
      • 標靶治療
    • 罕見疾病

第 8 章 融合蛋白市場：按最終用戶

  • 學術研究所
  • 生物製藥公司
  • 合約研究組織

第9章融合蛋白市場：依治療領域

  • 心血管疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染
  • 代謝紊亂
  • 腫瘤學
    • 造血系統惡性
    • 固態腫瘤

第10章美洲融合蛋白市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太融合蛋白市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲融合蛋白市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 1. Abcam plc
  • 2. Abnova Corporation
  • 3. ACROBiosystems Inc.
  • 4. Agilent Technologies, Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Cell Signaling Technology, Inc.
  • 7. Creative Diagnostics
  • 8. Enzo Life Sciences, Inc.
  • 9. GE Healthcare
  • 10. GenScript Biotech Corporation
  • 11. Merck KGaA
  • 12. OriGene Technologies, Inc.
  • 13. PeproTech, Inc.
  • 14. Promega Corporation
  • 15. ProSpec-Tany TechnoGene Ltd.
  • 16. R&D Systems, Inc.
  • 17. Rockland Immunochemicals, Inc.
  • 18. Santa Cruz Biotechnology, Inc.
  • 19. Sino Biological Inc.
  • 20. Thermo Fisher Scientific Inc.
Product Code: MRR-2B5802CFEB58

The Fusion Proteins Market was valued at USD 27.02 billion in 2023, expected to reach USD 29.58 billion in 2024, and is projected to grow at a CAGR of 10.49%, to USD 54.34 billion by 2030.

Fusion proteins, a revolutionary advancement in biotechnology, are engineered proteins formed by the genetic fusion of two distinct protein sequences, leading to the creation of a single polypeptide chain with multifaceted biological functions. This technology offers enhanced targeted delivery and therapeutic efficacy, making it indispensable in fields like oncology, autoimmune diseases, and enzyme replacement therapy. The application scope is broad, with uses in drug development and delivery systems, diagnostics, and even agriculture. End-users mainly include pharmaceutical and biotechnology companies, research institutions, and healthcare organizations. The fusion proteins market is poised for significant growth due to increasing demand for novel biologics, advancements in genetic engineering, and rising investments in the biotechnology sector. Key growth drivers involve escalating prevalence of chronic diseases, the necessity for cost-effective biopharmaceuticals, and technological advancements in protein engineering. There are burgeoning opportunities in the development of fusion proteins for immunotherapy and personalized medicine, driven by the need for targeted treatments. However, challenges persist, such as high R&D costs, stringent regulatory landscapes, and complex production processes that can hinder market growth. Ethical concerns and patent issues also pose limitations. To thrive, companies should focus on innovative technologies like CRISPR, AI-driven protein design, and advanced molecular techniques to enhance fusion protein specificity and stability. Collaborations and partnerships with academic and research institutions may also foster new discoveries and product developments. The market is dynamic, characterized by rapid technological advancements and competitive forces, urging companies to stay agile and adaptive. Innovating within synthetic biology and exploring new therapeutic areas that address unmet clinical needs can offer lucrative pathways for growth. Aspiring businesses should leverage these innovations and adopt strategies to streamline production and regulatory processes for optimal market penetration.

KEY MARKET STATISTICS
Base Year [2023] USD 27.02 billion
Estimated Year [2024] USD 29.58 billion
Forecast Year [2030] USD 54.34 billion
CAGR (%) 10.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fusion Proteins Market

The Fusion Proteins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of novel therapeutic approaches utilizing fusion proteins for targeted treatment of chronic diseases
    • Rising prevalence of cancer and autoimmune diseases driving demand for advanced fusion protein treatments
    • Expansion of pharmaceutical manufacturing capabilities and innovative technologies supporting fusion protein production
  • Market Restraints
    • High development and production costs of fusion proteins
  • Market Opportunities
    • Expansion of biopharmaceutical research focusing on multifunctional fusion proteins
    • Increasing investment in biotechnological R&D for the development of next-generation fusion proteins
  • Market Challenges
    • Stringent regulatory requirements on the production and commercialization of fusion proteins

Porter's Five Forces: A Strategic Tool for Navigating the Fusion Proteins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fusion Proteins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fusion Proteins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fusion Proteins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fusion Proteins Market

A detailed market share analysis in the Fusion Proteins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fusion Proteins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fusion Proteins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fusion Proteins Market

A strategic analysis of the Fusion Proteins Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fusion Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam plc, Abnova Corporation, ACROBiosystems Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Creative Diagnostics, Enzo Life Sciences, Inc., GE Healthcare, GenScript Biotech Corporation, Merck KGaA, OriGene Technologies, Inc., PeproTech, Inc., Promega Corporation, ProSpec-Tany TechnoGene Ltd., R&D Systems, Inc., Rockland Immunochemicals, Inc., Santa Cruz Biotechnology, Inc., Sino Biological Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Fusion Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Chemically Synthesized Fusion Proteins and Recombinant Fusion Proteins.
  • Based on Application, market is studied across Diagnostic Applications, Research Applications, and Therapeutic Applications. The Diagnostic Applications is further studied across Disease Diagnostics. The Research Applications is further studied across Drug Development and Proteomics Research. The Therapeutic Applications is further studied across Autoimmune Diseases, Oncology, and Rare Diseases. The Oncology is further studied across Cancer Immunotherapy and Targeted Therapy.
  • Based on End User, market is studied across Academic and Research Institutes, Biopharmaceutical Companies, and Contract Research Organizations.
  • Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, and Oncology. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Hematological Malignancies and Solid Tumors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of novel therapeutic approaches utilizing fusion proteins for targeted treatment of chronic diseases
      • 5.1.1.2. Rising prevalence of cancer and autoimmune diseases driving demand for advanced fusion protein treatments
      • 5.1.1.3. Expansion of pharmaceutical manufacturing capabilities and innovative technologies supporting fusion protein production
    • 5.1.2. Restraints
      • 5.1.2.1. High development and production costs of fusion proteins
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of biopharmaceutical research focusing on multifunctional fusion proteins
      • 5.1.3.2. Increasing investment in biotechnological R&D for the development of next-generation fusion proteins
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements on the production and commercialization of fusion proteins
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fusion Proteins Market, by Product Type

  • 6.1. Introduction
  • 6.2. Chemically Synthesized Fusion Proteins
  • 6.3. Recombinant Fusion Proteins

7. Fusion Proteins Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostic Applications
    • 7.2.1. Disease Diagnostics
  • 7.3. Research Applications
    • 7.3.1. Drug Development
    • 7.3.2. Proteomics Research
  • 7.4. Therapeutic Applications
    • 7.4.1. Autoimmune Diseases
    • 7.4.2. Oncology
      • 7.4.2.1. Cancer Immunotherapy
      • 7.4.2.2. Targeted Therapy
    • 7.4.3. Rare Diseases

8. Fusion Proteins Market, by End User

  • 8.1. Introduction
  • 8.2. Academic and Research Institutes
  • 8.3. Biopharmaceutical Companies
  • 8.4. Contract Research Organizations

9. Fusion Proteins Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Infectious Diseases
    • 9.3.1. Bacterial Infections
    • 9.3.2. Viral Infections
  • 9.4. Metabolic Disorders
  • 9.5. Oncology
    • 9.5.1. Hematological Malignancies
    • 9.5.2. Solid Tumors

10. Americas Fusion Proteins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Fusion Proteins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Fusion Proteins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abcam plc
  • 2. Abnova Corporation
  • 3. ACROBiosystems Inc.
  • 4. Agilent Technologies, Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Cell Signaling Technology, Inc.
  • 7. Creative Diagnostics
  • 8. Enzo Life Sciences, Inc.
  • 9. GE Healthcare
  • 10. GenScript Biotech Corporation
  • 11. Merck KGaA
  • 12. OriGene Technologies, Inc.
  • 13. PeproTech, Inc.
  • 14. Promega Corporation
  • 15. ProSpec-Tany TechnoGene Ltd.
  • 16. R&D Systems, Inc.
  • 17. Rockland Immunochemicals, Inc.
  • 18. Santa Cruz Biotechnology, Inc.
  • 19. Sino Biological Inc.
  • 20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. FUSION PROTEINS MARKET RESEARCH PROCESS
  • FIGURE 2. FUSION PROTEINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FUSION PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FUSION PROTEINS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FUSION PROTEINS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES FUSION PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES FUSION PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. FUSION PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. FUSION PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FUSION PROTEINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FUSION PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FUSION PROTEINS MARKET DYNAMICS
  • TABLE 7. GLOBAL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FUSION PROTEINS MARKET SIZE, BY CHEMICALLY SYNTHESIZED FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FUSION PROTEINS MARKET SIZE, BY RECOMBINANT FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FUSION PROTEINS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FUSION PROTEINS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FUSION PROTEINS MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FUSION PROTEINS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FUSION PROTEINS MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FUSION PROTEINS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FUSION PROTEINS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL FUSION PROTEINS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL FUSION PROTEINS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL FUSION PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL FUSION PROTEINS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL FUSION PROTEINS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL FUSION PROTEINS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL FUSION PROTEINS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL FUSION PROTEINS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL FUSION PROTEINS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES FUSION PROTEINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. TAIWAN FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. THAILAND FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. VIETNAM FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 245. DENMARK FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. DENMARK FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. DENMARK FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 255. EGYPT FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. EGYPT FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. EGYPT FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. FINLAND FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. FINLAND FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. FINLAND FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. FRANCE FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. FRANCE FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. FRANCE FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 285. GERMANY FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. GERMANY FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. GERMANY FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 295. ISRAEL FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. ISRAEL FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. ISRAEL FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. ITALY FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. ITALY FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 307. ITALY FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 309. ITALY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 315. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 318. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 319. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 325. NIGERIA FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. NIGERIA FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. NIGERIA FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 328. NIGERIA FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 329. NIGERIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 330. NIGERIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 331. NIGERIA FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 335. NORWAY FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. NORWAY FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. NORWAY FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 338. NORWAY FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 339. NORWAY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. NORWAY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. NORWAY FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY FUSION PROTEINS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 345. POLAND FUSION PROTEINS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. POLAND FUSION PROTEINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 347. POLAND FUSION PROTEINS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 348. POLAND FUSION PROTEINS MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 349. POLAND FUSION PROTEINS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 350. POLAND FUSION PROTEINS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 351. POLAND FUSION PROTEINS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)